Research
Adherence
In real-world clinical practice, approximately half of patients initiating oral semaglutide for Type 2 Diabetes Mellitus remain on their initial treatment regimen without change for at least 6 months.
If you start oral semaglutide for Type 2 Diabetes, there is a roughly 50% chance you will stay on that exact treatment plan for the next six months without needing to switch or add other diabetes medications. This stability is a common and successful real-world outcome, not a sign that treatment is failing.
GoodSupportsHIGH confidence
Among patients who initiated oral semaglutide, 49.0% remained on their initial regimen over the 6-month follow-up period
Why this rating
Large sample size (n=1937) and real-world data, but limited to a short 6-month follow-up period.
Source
Real-World Treatment Patterns Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral Semaglutide
Caroline Swift et al. · Diabetes Therapy · 2024
cohort · n=1937Cited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →